{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.6","upperLimit":"92.8","value":"84.5"},{"groupId":"OG001","lowerLimit":"57.3","upperLimit":"85.5","value":"74.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"One-year PFS rate is defined as the percentage (%) of participants surviving 1 year after randomization without progression to multiple myeloma or death estimated by the Kaplan-Meier method and based on the International Myeloma Working Group (IMWG) calcium, renal, anemia, and bone lesions (CRAB) criteria. Progressive disease (PD) is defined as presence of an M- component in serum plus clonal plasma cells in the bone marrow plus 1 or more of the following: Calcium elevation (greater than \\[\\>\\] 11.5 milligram per deciliter \\[mg/dL\\] \\[\\> 2.88 millimoles per liter {mmol/L}\\]); Renal insufficiency (creatinine \\> 2 mg/dL \\[177 micromoles per liter or more\\]; Anemia (hemoglobin less than \\[\\<\\] 10 gram per deciliter \\[g/dL\\] or 2 g/dL lower than lower limit of normal \\[LLN\\] \\[hemoglobin \\< 6.5 mmol/L or 1.25 mmol/L lower than LLN\\]); Bone disease (lytic lesions or osteopenia).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 15 milligram per kilogram (mg/kg) of siltuximab as a 1-hour intravenous (IV) infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG000","title":"Siltuximab"},{"description":"Participants received placebo as a 1-hour IV infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat (ITT) population included participants who were randomly assigned to siltuximab or placebo treatment group based on an integrated voice response system (IVRS).","reportingStatus":"POSTED","timeFrame":"Up to 1 Year","title":"One-Year Progression-Free Survival (PFS) Rate","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}